OLMA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Olema Pharmaceuticals Inc (OLMA) is not a strong buy for a beginner, long-term investor at this moment. While the stock has potential upside due to its promising drug pipeline and positive analyst sentiment, the technical indicators, lack of recent news catalysts, and weak financial performance suggest that it is better to wait for clearer signs of momentum or fundamental improvement before investing.
The MACD is below zero and negatively contracting, indicating bearish momentum. RSI is neutral at 32.658, not signaling oversold or overbought conditions. The stock is trading near its support level of 23.012, but no clear upward trend is visible. Moving averages are converging, suggesting a lack of directional bias.
Analysts have consistently raised price targets, with the most recent targets ranging from $38 to $60, citing the promising potential of Olema's lead drug, palazestrant, in the large ER+/HER2- breast cancer market. The biotech sector is also expected to recover in 2026, which could benefit OLMA.
The company's financials remain weak, with negative net income (-$42.2M) and declining EPS (-18.33% YoY). Technical indicators do not show a strong bullish trend, and there is no recent news or congress trading data to act as a catalyst.
In Q3 2025, the company reported zero revenue, with net income improving slightly by 22.17% YoY but still negative at -$42.2M. EPS dropped by 18.33% YoY, reflecting ongoing financial struggles.
Analysts are highly optimistic about the stock, with multiple 'Buy' ratings and price targets ranging from $38 to $60. Analysts highlight the potential of palazestrant and the large market opportunity in ER+/HER2- breast cancer. However, the stock's immediate upside may depend on upcoming trial results and broader biotech sector recovery.
